Value Creation in the Pharmaceutical Industry

Introduction to the Book
Global Epidemiological Developments
The Value of Pharmaceutical Innovation: Concepts and Assessment
A Review of the Pharmaceutical R&D Efficiency: Costs, Timelines and Probabilities
Financing Pharmaceutical Innovation
Challenges And Options For Drug Discovery
Translational Medicine - Enabling the Proof of Concepts
Preclinical Safety and Risk Assessment
Developing Commercial Solutions for Therapeutic Proteins
The Evolution of Clinical Development: From Technical Success to Clinical Value Creation
Translational Development
40 years of Innovation in Biopharmaceuticals - Will the Next 40 Years be as Revolutionary?
Vaccines - Where Inertia, Innovation and Revolution Create Value, Simultaneously and Quietly
The Patient Centric Pharma Company: Evolution, Reboot or Revolution?
The Pharmaceutical Industry is Opening its R&D Boundaries
Out-licensing in Pharmaceutical Research and Development
Trends and Innovations in Pharmaceutical R&D Outsourcing
New Innovation Models in Pharmaceutical R&D
The Influence of Leadership Paradigms and Styles on Pharmaceutical Innovation
The Role of Modern Portfolio Management in Pharma Innovation
Patent Management throughout the Innovation Life Cycle
The Pharmaceutical Industry in Search of the Next Wave of Commercially Relevant Innovation

Prof. Dr. Alexander Schuhmacher is a professor for R&D management, Vice Dean of the Faculty of Applied Chemistry and Senator at Reutlingen University. And he is Director for R&D performance metrics and business model innovation at Bioscience Valuation. Before joining the academic world, he worked 14 years in the pharmaceutical industry in various functions in R&D, such as in R&D portfolio management and strategic planning. He studied biology at the University of Constance (Germany), Pharmaceutical Medicine at Witten-Herdecke University (Germany) and he is also a graduate of the Executive MBA program at the University of St. Gallen (Switzerland).

Prof. Dr. Markus Hinder studied medicine at the Universities of Heidelberg, Paris and Zürich and obtained a doctoral degree in pharmacology from Heidelberg University. After graduation he trained in clinical pharmacology, cardiology and emergency medicine. Before joining Novartis he held leadership positions in clinical pharmacology, translational medicine, clinical development, medical affairs and project management. Markus is a professor at Cardiff University/ Hochschule Fresenius, reviewer for several journals and associate editor for the Journal of Translational Medicine.

Prof. Dr. Oliver Gassmann is a Professor for technology and innovation management at St. Gallen University, where he chairs the Institute of Technology Management. His teaching activities include several executive MBA programs. He has written or edited 18 books and published more than 300 journal articles on technology and innovation management. Until 2002 he headed the R&D department of Schindler. The main focus of his research lies in open innovation and global innovation processes. He is the 1998 recipient of the RADMA Prize and in 2009 was elected among the top 50 researchers by IAMOT, the International Association for Management of Technology.

A. Schuhmacher, Reutlingen University of Applied Science, Germany; M. Hinder, Novartis Institutes for Biomedical Research, Basel, Switzerland; O. Gassmann, University of St. Gallen, Switzerland